Rist R J, Naftalin R J
Biomedical Sciences Division (Physiology), King's College London, U.K.
Biochem J. 1991 Aug 15;278 ( Pt 1)(Pt 1):129-35. doi: 10.1042/bj2780129.
Dexamethasone decreases 2-D-deoxyglucose (2-dGlc) uptake and accumulation into rat peritoneal macrophages in vitro in a concentration- and time-dependent manner (Ki for 1 microM-dexamethasone after a 2 h exposure = 0.71 +/- 0.21 microM; Ki for 0.1 microM-dexamethasone after exposure for 4 h = 0.10 +/- 0.06 microM). The inhibition of 2-dGlc uptake is consistent with a decrease in the coupling between endofacial hexokinase activity and the sugar transporter. The evidence for this is: (1) the Km for zero-trans 2-dGlc uptake in quiescent macrophages was increased by dexamethasone, but there was no significant effect on the Vmax.; (2) dexamethasone increased the rate of exit of sugar from cells preloaded with 2-dGlc; (3). the free sugar accumulation within the cytosol of the cells above the external solution concentration was significantly decreased by dexamethasone. These effects of dexamethasone on 2-dGlc transport were antagonized by simultaneous exposure to the steroid RU 38486 (Ki = 0.04 +/- 0.01 microM; 4 h incubation). Although dexamethasone inhibited zero-trans uptake, the maximum rate of infinite-trans exchange uptake of 2-dGlc into cells preloaded with 3-O-methyl-D-glucose (40 mM) was unaltered by dexamethasone or RU 38486, indicating that the dexamethasone-dependent decrease in zero-trans uptake was not due to a change in the number of transporters in the plasma membrane. Dexamethasone also inhibited the phorbol myristate acetate-induced stimulation of hexose monophosphate shunt (HMPS) activity, and this was reversed by RU 38486. Cytochalasin B, the potent sugar-transport inhibitor, inhibited HMPS activity and 2-d[2,6-3H]Glc uptake equally, indicating a single site of action. By contrast, dexamethasone showed differential inhibition of HMPS activity and 2-d[2,6-3H]Glc uptake, suggesting that it not only acts by decreasing the coupling between hexokinase and sugar transport, but also at one or more additional points.
地塞米松以浓度和时间依赖性方式降低体外培养的大鼠腹腔巨噬细胞对2-脱氧葡萄糖(2-dGlc)的摄取和积累(暴露2小时后1微摩尔地塞米松的Ki = 0.71±0.21微摩尔;暴露4小时后0.1微摩尔地塞米松的Ki = 0.10±0.06微摩尔)。2-dGlc摄取的抑制与内膜己糖激酶活性和糖转运体之间偶联的减少一致。支持这一点的证据是:(1)地塞米松使静止巨噬细胞中零转运2-dGlc摄取的Km增加,但对Vmax没有显著影响;(2)地塞米松增加了预先加载2-dGlc的细胞中糖的流出速率;(3)地塞米松显著降低了细胞胞质溶胶中高于外部溶液浓度的游离糖积累。地塞米松对2-dGlc转运的这些作用被同时暴露于类固醇RU 38486(Ki = 0.04±0.01微摩尔;孵育4小时)所拮抗。尽管地塞米松抑制零转运摄取,但预先加载3-O-甲基-D-葡萄糖(40毫摩尔)的细胞中2-dGlc的无限转运交换摄取的最大速率不受地塞米松或RU 38486的影响,表明地塞米松依赖性的零转运摄取减少不是由于质膜中转运体数量的变化。地塞米松还抑制佛波酯肉豆蔻酸酯乙酸盐诱导的磷酸己糖旁路(HMPS)活性的刺激,并且这被RU 38486逆转。细胞松弛素B,一种有效的糖转运抑制剂,同样抑制HMPS活性和2-d[2,6-3H]Glc摄取,表明作用位点单一。相比之下,地塞米松对HMPS活性和2-d[2,6-3H]Glc摄取表现出差异抑制,表明它不仅通过减少己糖激酶和糖转运之间的偶联起作用,还作用于一个或多个其他位点。